Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study)

Abstract

Background: MicroRNAs (miRNAs) are associated with cardiovascular disease and control gene expression and are detectable in the circulation.

Objective: The purpose of this study was to test the hypothesis that circulating miRNAs may be associated with atrial fibrillation (AF).

Methods: Using a prospective study design powered to detect subtle differences in miRNAs, we quantified plasma expression of 86 miRNAs by high-throughput quantitative reverse transcriptase-polymerase chain reaction in 112 participants with AF and 99 without AF. To examine parallels between cardiac and plasma miRNA profiles, we quantified atrial tissue and plasma miRNA expression using quantitative reverse transcriptase-polymerase chain reaction in 31 participants undergoing surgery. We also explored the hypothesis that lower AF burden after ablation would be reflected in the circulating blood pool by examining change in plasma miRNAs after AF ablation (n = 47).

Results: Mean age of the cohort was 59 years; 58% of participants were men. Plasma miRs-21 and 150 were 2-fold lower in participants with AF than in those without AF after adjustment (P ≤.0006). Plasma levels of miRs-21 and 150 also were lower in participants with paroxysmal AF than in those with persistent AF (P <.05). Expression of miR-21, but not of miR-150, was lower in atrial tissue from patients with AF than in those without AF (P <.05). Plasma levels of miRs-21 and 150 increased 3-fold after AF ablation (P ≤.0006).

Conclusion: Cardiac miRs-21 and 150 are known to regulate genes implicated in atrial remodeling. Our findings show associations between plasma miRs-21 and 150 and AF, suggesting that circulating miRNAs can provide insights into cardiac gene regulation.

Keywords: Arial fibrillation; Circulation; Epidemiology; MicroRNA; Risk factor.

Conflict of interest statement

Conflicts of interest: None.

Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Figures

Figure 1

Plasma levels of miR-21 and 150 are lower in plasma of patients with AF compared to controls (A). Plasma levels of miR-21 and 150 increase after ablation (B). Tissue levels of miR-21 are lower in patients with AF compared to controls (C).

Figure 2

Plasma levels of miR-21 and 150 are lower in patients with persistent as compared to paroxysmal AF.